

# Anton Ilich

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6065617/publications.pdf>

Version: 2024-02-01

23  
papers

489  
citations

933447

10  
h-index

713466

21  
g-index

23  
all docs

23  
docs citations

23  
times ranked

745  
citing authors

#	ARTICLE	IF	CITATIONS
1	Contact and intrinsic coagulation pathways are activated and associated with adverse clinical outcomes in COVID-19. <i>Blood Advances</i> , 2022, 6, 3367-3377.	5.2	17
2	<scp>Antithrombinâ€œ</scp> mitigates thrombinâ€œmediated endothelial cell contraction and sickle red blood cell adhesion in microscale flow. <i>British Journal of Haematology</i> , 2022, 198, 893-902.	2.5	3
3	Tranexamic acid rapidly inhibits fibrinolysis, yet transiently enhances plasmin generation in vivo. <i>Blood Coagulation and Fibrinolysis</i> , 2021, 32, 172-179.	1.0	6
4	Plasmin-mediated Cleavage of High Molecular Weight Kininogen Contributes to Acetaminophen-Induced Acute Liver Failure. <i>Blood</i> , 2021, 138, 259-272.	1.4	14
5	Euglobulin clot lysis time reveals a high frequency of fibrinolytic activation in trauma. <i>Thrombosis Research</i> , 2021, 204, 22-28.	1.7	6
6	Pathologically stiff erythrocytes impede contraction of blood clots: Comment. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2893-2894.	3.8	2
7	Cleavage of High Molecular Weight Kininogen and Bradykinin Release By Red Blood Cell Microvesicles As a Putative Mechanism for Hypotensive Transfusion Reactions. <i>Blood</i> , 2021, 138, 3240-3240.	1.4	1
8	Development and application of global assays of hyperâ€œand hypofibrinolysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 46-53.	2.3	23
9	D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer. <i>Oncologist</i> , 2020, 25, 1075-1083.	3.7	9
10	Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer. <i>Thrombosis Research</i> , 2020, 196, 437-443.	1.7	0
11	Biomarkers in cancer patients at risk for venous thromboembolism: data from the AVERT study. <i>Thrombosis Research</i> , 2020, 191, S31-S36.	1.7	10
12	Red blood cell adhesion to ICAM-1 is mediated by fibrinogen and is associated with right-to-left shunts in sickle cell disease. <i>Blood Advances</i> , 2020, 4, 3688-3698.	5.2	28
13	Protease: Serpin complexes to assess contact system and intrinsic pathway activation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 789-798.	2.3	8
14	Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways. <i>Blood</i> , 2020, 135, 755-765.	1.4	61
15	The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues. <i>British Journal of Cancer</i> , 2019, 121, 359-371.	6.4	78
16	Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease. <i>Blood</i> , 2019, 133, 2529-2541.	1.4	51
17	Enhanced VTE Risk Stratification in Ambulatory Patients with Cancer. <i>Blood</i> , 2019, 134, 634-634.	1.4	1
18	Red blood cell adhesion to hemeâ€œactivated endothelial cells reflects clinical phenotype in sickle cell disease. <i>American Journal of Hematology</i> , 2018, 93, 1050-1060.	4.1	36

#	ARTICLE	IF	CITATIONS
19	Histones Induce the Release of Extracellular Hemoglobin and Red Blood Cell-Derived Microvesicles with Procoagulant Activity. <i>Blood</i> , 2018, 132, 2514-2514.	1.4	2
20	Global assays of fibrinolysis. <i>International Journal of Laboratory Hematology</i> , 2017, 39, 441-447.	1.3	70
21	Global assays of fibrinolysis. <i>International Journal of Laboratory Hematology</i> , 2017, 39, e142-e143.	1.3	8
22	Thrombin generation and cell-dependent hypercoagulability in sickle cell disease. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1941-1952.	3.8	53
23	Alteration of the Structure and Dynamics of Venous Clot Formation in Human and Murine Sickle Cell Disease. <i>Blood</i> , 2016, 128, 2478-2478.	1.4	2